文献速递白血病

翻译组蛋白质组学鉴定自噬为急性髓系白血病中靶向FLT3抑制剂的原发性耐药机制

Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2022-08-23

该研究利用翻译组蛋白质组学与磷酸化蛋白质组学,系统分析FLT3-ITD阳性急性髓系白血病细胞对多种靶向FLT3抑制剂的急性细胞反应,发现AKT-mTORC1-ULK1依赖的自噬是主要耐药机制;药物或基因抑制自噬可增加细胞系、患者来源异种移植瘤及原代AML细胞对FLT3靶向治疗的敏感性,小鼠体内联合口服FLT3和自噬抑制剂协同延缓白血病进展并延长总生存。

要点

  • 靶向FLT3抑制剂在FLT3-ITD阳性细胞中浓度和时间依赖性诱导自噬。
  • AKT-mTORC1-ULK1依赖的自噬是靶向FLT3抑制剂治疗的主要耐药机制。
  • 药物或基因抑制自噬可增加FLT3靶向治疗敏感性,小鼠中联合治疗协同延长生存。

核心结论

  • 研究确定了导致靶向FLT3抑制剂原发性治疗耐药的分子机制,并证明了同时靶向FLT3和自噬诱导的合理联合治疗策略的临床前疗效。

研究设计与样本

  • 采用新开发的翻译组蛋白质组学(测量新生蛋白质组变化)结合磷酸化蛋白质组学,系统研究FLT3-ITD阳性AML细胞对多种靶向FLT3抑制剂(quizartinib、crenolanib和gilteritinib)的急性细胞反应,并在体外细胞系、患者来源异种移植瘤、原代人类AML细胞及小鼠异种移植模型中验证。

主要发现

  • 靶向FLT3抑制剂在体外FLT3-ITD阳性细胞及离体原代人类AML细胞中浓度和时间依赖性诱导自噬。
  • 药物或基因抑制自噬增加了细胞系、患者来源异种移植瘤和离体原代AML细胞对FLT3靶向治疗的敏感性。
  • 在移植FLT3-ITD阳性AML细胞的小鼠中,口服FLT3抑制剂与自噬抑制剂联合治疗协同损害白血病进展并延长总生存。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Internal tandem duplications (ITD) in the receptor tyrosine kinase FLT3 occur in 25 % of acute myeloid leukemia (AML) patients, drive leukemia progression and confer a poor prognosis. Primary resistance to FLT3 kinase inhibitors (FLT3i) quizartinib, crenolanib and gilteritinib is a frequent clinical challenge and occurs in the absence of identifiable genetic causes. This suggests that adaptive cellular mechanisms mediate primary resistance to on-target FLT3i therapy. Here, we systematically investigated acute cellular responses to on-target therapy with multiple FLT3i in FLT3-ITD + AML using recently developed functional translatome proteomics (measuring changes in the nascent proteome) with phosphoproteomics. This pinpointed AKT-mTORC1-ULK1-dependent autophagy as a dominant resistance mechanism to on-target FLT3i therapy. FLT3i induced autophagy in a concentration- and time-dependent manner specifically in FLT3-ITD + cells in vitro and in primary human AML cells ex vivo. Pharmacological or genetic inhibition of autophagy increased the sensitivity to FLT3-targeted therapy in cell lines, patient-derived xenografts and primary AML cells ex vivo. In mice xenografted with FLT3-ITD + AML cells, co-treatment with oral FLT3 and autophagy inhibitors synergistically impaired leukemia progression and extended overall survival. Our findings identify a molecular mechanism responsible for primary FLT3i treatment resistance and demonstrate the pre-clinical efficacy of a rational combination treatment strategy targeting both FLT3 and autophagy induction.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Koschade SE, Klann K, Shaid S, et al. Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia. Leukemia. 2022. PMID: 35999260. doi:10.1038/s41375-022-01678-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。